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Abstract
 
Using transgenic mice that replicate hepatitis B virus (HBV) at high levels in the liver as recip-
ients of HBV-specific cytotoxic T lymphocytes (CTLs), we showed that the chemokines re-
 
sponsive to 
 

 
–2/IFN-
 

 
 inducible protein ([Crg2]IP-10) and monokine induced by interferon
 
-
 

 
(Mig) are rapidly and strongly induced in the liver after CTL transfer. The transferred CTLs
produce neither chemokine; rather, they activate (via the secretion of IFN-
 

 
) hepatocytes and
nonparenchymal cells of the liver to produce (Crg2)IP-10 and Mig. Importantly, blocking
these chemokines in vivo reduces the recruitment of host-derived lymphomononuclear cells
into the liver and the severity of the liver disease without affecting the IFN-
 

 
–dependent anti-
viral potential of the CTLs. The finding that neutralization of these chemokines is associated
with maintenance of antiviral effects but diminished tissue damage may be significant for the
development of immunotherapeutic approaches for the treatment of chronic HBV infection.
Key words: chemokines • hepatitis B virus • infectious immunity-virus • liver
 
Introduction
 
The hepatitis B virus (HBV)
 
*
 
 is an enveloped DNA virus
which causes acute and chronic liver disease characterized
by a necroinflammatory lymphomononuclear cell infiltrate
and Kupffer cell hyperplasia (1). Since HBV is not directly
cytopathic for the hepatocyte, the immune response to vi-
ral antigens is thought to be responsible for both liver dis-
ease and viral clearance after HBV infection. Indeed, pa-
tients with acute viral hepatitis, who successfully clear the
virus, mount a multispecific polyclonal CTL response to
several HBV-encoded antigens (1, 2). In contrast, this re-
sponse is absent or extremely weak in chronically infected
patients who do not clear the virus (1, 2) and thus, it is be-
lieved that the outcome of HBV infection (viral clearance
versus viral persistence) is determined primarily by the
vigor and quality of the cellular immune response (1, 2).
The experimental approaches to HBV pathogenesis have
been difficult because the host range of HBV is limited to
man and chimpanzees, and because in vitro systems for the
propagation of HBV do not exist. To overcome these lim-
itations, we developed and characterized transgenic mice
that replicate HBV at high levels in the liver (3). These an-
imals are profoundly immunologically tolerant to the virus
(4). We examined in this model the antiviral and immuno-
pathological consequences of antigen recognition by ad-
ministration of H2
 
d
 
-restricted CTL clones that recognize a
dominant CTL epitope located between residues 28–39 of
 
Address correspondence to Luca G. Guidotti, The Scripps Research Insti-
tute, Dept. of Molecular and Experimental Medicine, 10550 North Tor-
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*
 
Abbreviations used in this paper:
 
 (Crg2)IP-10, chemokine responsive to
 

 
–2/IFN-
 

 
 inducible protein; HBV, hepatitis B virus; HBeAg, hepatitis
Be antigen; HCV, hepatitis C virus; IHL, intrahepatic lymphocyte; MCP,
monocyte chemotactic protein; Mig, monokine induced by IFN-
 

 
; MIP,
macrophage inflammatory protein; NRS, normal rabbit preimmune se-
rum; RPA, RNase protection assay; sALT, serum alanine aminotransferase.
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HBsAg (5, 6). Surprisingly, the antiviral potential of the
CTLs was shown to be primarily mediated by noncytolytic
mechanisms that involve the intrahepatic production of
IFN-
 

 
 by the CTLs after antigen recognition (6, 7). The
noncytolytic potential of the CTLs was confirmed by dem-
onstrating that HBsAg-specific perforinless CTLs abolished
viral replication in the complete absence of liver disease (6).
By crossing HBV transgenic mice with mice genetically
deficient for IFN-
 

 
, recent studies have shown that this cy-
tokine mediates most of the antiviral effect of the CTLs (8).
We also showed that the cytopathic potential of the
CTLs is quite limited, involving the apoptotic death of a
small number of hepatocytes and resulting in widely scat-
tered, acidophilic, Councilman bodies (apoptotic hepato-
cytes) that are characteristic of acute viral hepatitis in man
(5). As time progresses, however, many host-derived in-
flammatory cells are recruited into the liver, thereby con-
tributing to the formation of necroinflammatory foci in
which apoptotic hepatocytes and CTLs are outnumbered
by host-derived lymphomononuclear and polymorphonu-
clear cells (5, 9). These recruited inflammatory cells could
be responsible for antigen-nonspecific amplification mech-
anisms that may cause much of the liver damage initiated
by the CTLs. The recruitment of inflammatory cells that
are involved in this amplification process is likely to be
mediated by the secretion of chemokines by either the an-
tigen-activated CTLs or by other cellular components of
the liver.
Chemokines are small proteins that regulate the traffick-
ing of inflammatory cells to tissue sites of inflammation
(10, 11). Most chemokines share four cysteine residues that
are thought to be crucial for the tertiary structure of the
proteins. Chemokines have been divided into four differ-
ent families (C-X-C, CC, CX
 
3
 
C, and C) depending on
the position of the first two cysteine residues (10, 11).
Since CTLs are very efficient in their property of specifi-
cally recognizing virally infected cells in the periphery, it is
tempting to speculate that their capacity of secreting che-
mokines coupled with their capacity of inducing chemo-
kine production by neighboring cells may help to orches-
trate the trafficking, homing, and effector functions of the
cellular immune response (12). This may turn out to be
particularly relevant in the case of infections with noncyto-
pathic viruses (like HBV) which are not known to elicit
the strong, nonspecific inflammatory responses that are
common during infections with viruses that directly cause
tissue damage (12).
Recent reports have shown that several chemokines are
induced in infected tissues during different viral infections.
Among them, C-X-C chemokines such as chemokine
responsive to 
 

 
–2/IFN-
 

 
 inducible protein, CXCL10
([Crg2]IP-10) and monokine induced by IFN-
 
 
 
(Mig),
CXCL9 are thought to play an important role in viral im-
munity. Both chemokines are known to be produced
by macrophages, bind the same chemokine receptor
(CXCR3), and chemoattract lymphocytes and monocyte/
macrophages (10, 11). A recent report has also shown that
these same chemokines can be produced by primary hepa-
 
tocyte cultures derived from mice treated with IL-2/IL-12
(13). (Crg2)IP-10 and Mig are induced in the mouse liver
during vaccinia virus infection (14) and mice infected with
recombinant vaccinia virus encoding either chemokine re-
solve the infection much more successfully than mice in-
fected with control virus (15). Similarly, mouse hepatitis
virus–infected mice treated with Abs specific for (Crg2)IP-
10 or Mig showed decreased T cell infiltration in the brain,
delayed viral clearance, and increased mortality (16, 17).
Recent studies have also shown that Mig contributes to
protection against MCMV infection (18). Finally, it is
worth mentioning that IP-10 and Mig have been detected
in the liver of patients chronically infected with hepatitis C
virus (HCV; references 19 and 20). To our knowledge, no
information is available about the role of (Crg2)IP-10 or
Mig in HBV pathogenesis.
Based on the aforementioned studies, it is possible that
(Crg2)IP-10 and/or Mig might play a role in the intrahe-
patic recruitment, antiviral, and pathogenetic effector func-
tions of HBV-specific CTLs and/or other inflammatory
cells during HBV infection. To test this hypothesis, we
took advantage of our HBV transgenic mouse model to
perform a series of experiments aimed at monitoring (i) the
ability of passively transferred CTLs to induce (Crg2)IP-10
and Mig in the liver; (ii) the source, kinetics, and regulation
of (Crg2)IP-10 and Mig expression in our system; and (iii)
the ability of chemokine-specific neutralizing Abs to mod-
ulate their function(s).
 
Materials and Methods
 
Mice.
 
HBV transgenic mouse lineages 1.3.32 and 1.3.46 used
in this study have been described previously (3). Lineage 1.3.32
(inbred C57BL/6, H-2
 
b
 
) was bred one generation against BALB/c
mice (H-2
 
d
 
) to produce H-2
 
bxd
 
 F
 
1
 
 hybrids before injection of
H-2
 
d
 
 restricted HBsAg-specific CTL lines and clones. Lineage
1.3.46 (inbred B10D2, H-2
 
d
 
) was backcrossed against mice ge-
netically deficient for IFN-
 

 
 (IFN-
 

 

 
/
 

 
) as described previously
(8). In all experiments, the mice were matched for age (8 wk),
sex, and hepatitis Be antigen (HBeAg) levels in their serum be-
fore experimental manipulations. All animals were housed in
pathogen-free rooms under strict barrier conditions.
 
Injection of HBsAg-specific CTL Lines and Clones.
 
HBV trans-
genic mice were injected with a HBsAg-specific, H-2
 
d
 
 restricted,
CD8
 

 
 CTL clone (designated 6C2) that recognizes an epitope
(IPQSLDSWWTSL) located between residues 28–39 of HBsAg
(9). Clone 6C2 was maintained as described previously (9). 5 d
after the last stimulation, the cells were washed, counted, and in-
jected intravenously into HBV transgenic mice. Mice were killed
at different time points after injection and their livers were per-
fused and harvested for histological, histochemical, and flow cy-
tometry analyses, or they were snap frozen in liquid nitrogen and
stored at 
 

 
80
 

 
C for subsequent molecular analyses (see below).
 
Anticytokine and Antichemokine Abs.
 
Hamster mAbs H22 spe-
cific for murine IFN-
 

 
 (21) and control hamster IgG (Jackson
ImmunoResearch Laboratories) were used. Mice were injected
intraperitoneally (250 
 

 
g/mouse) 16 h before the intravenous in-
jection of the CTLs. The rabbit polyclonal Abs specific for mouse
(Crg2)IP-10 or Mig and the preimmune normal rabbit serum
used in this study have been described previously (16, 17). 1 ml
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of either a cocktail of anti–(Crg2)IP-10 and anti-Mig rabbit Ig or
normal rabbit preimmune serum (NRS) was administered intra-
peritoneally into HBV transgenic mice twice, first 16 h before and
then simultaneously with the intravenous injection of the CTLs.
 
Tissue DNA and RNA Analyses.
 
Total DNA and RNA were
isolated from frozen livers (left lobe) and analyzed for HBV DNA
by Southern blot analysis and chemokine, chemokine receptor,
cytokine, T lymphocyte, and macrophage marker mRNAs by
RNase protection exactly as described previously (3, 8, 22). The
relative abundance of specific DNA and RNA molecules was de-
termined by PhosphorImaging analysis, using the Optiquant™
image analysis software (Packard Instrument Co.).
 
Biochemical and Histological Analyses.
 
The extent of hepatocel-
lular injury was monitored by measuring serum alanine ami-
notransferase (sALT) activity at multiple time points after treat-
ment. sALT activity was measured in a Paramax chemical
analyzer (Baxter Diagnostics, Inc.) exactly as described previously
(6). For histological analysis, liver was fixed in 10% zinc-buffered
formalin (Anatech), embedded in paraffin, sectioned (3 
 

 
m), and
stained with H&E (6). Quantitative morphometric analysis of the
number and size of intrahepatic inflammatory foci (scored as ap-
optotic hepatocytes and inflammatory cells) was performed by
counting 
 

 
100 high power (original magnification: 
 

 
400) fields
(hpf) representing 4 mm
 
2
 
 of liver tissue.
 
In Situ Hybridization.
 
This procedure was performed exactly
as described previously (3). For (Crg2)IP-10, a cDNA fragment
(726-bp) was synthesized and cloned in pGEM4 (Promega) as de-
scribed previously (22). For Mig, a cDNA fragment spanning nu-
cleotides-101–402 of the murine Mig gene (GenBank/EMBL/
DDBJ M34815) was synthesized by RT-PCR and after sequence
verification cloned in pGEM4. The 
 
33
 
[P]-labeled RNA probes
used for in situ hybridization were generated by T7-driven tran-
scription of 1 
 

 
g of linearized plasmids containing (Crg2)IP-10–
or Mig-specific sequences.
 
Isolation and Analysis of the Intrahepatic Leukocytes.
 
Mouse liv-
ers were weighed at the time of autopsy. intrahepatic leukocytes
(IHLs) were isolated from two liver lobes of a known weight and
analyzed by flow cytometry. Single cell suspensions were pre-
pared from the two liver lobes and analysis of the IHL population
was performed by flow cytometry, exactly as described previously
(references 23 and 24). The cells were surface stained with FITC-
or phycoerythrin-labeled anti-CD4, anti-CD8, anti-CD3, anti-
DX-5, anti-NK1.1, anti-CD19, anti-Gr-1, anti-CD11b, and
anti-CD11c Abs (BD PharMingen) for the detection of NK1.1
 

 
/
CD3
 

 
 and DX5
 

 
 cells (NK cells), CD3
 

 
/NK1.1
 

 
 cells (T cells),
CD3
 

 
/NK1.1
 

 
 cells (NKT cells), CD8
 

 
 cells (mostly CTLs),
CD4
 

 
 (mostly Th cells), CD11b
 

 
/CD11c
 

 
 (mostly lymphoid
dendritic cells), CD11b
 

 
/CD11c
 

 
 cells (mostly myeloid den-
dritic cells), CD11b
 

 
/CD11c
 

 
 (mostly macrophages), CD19
 

 
 (B
cells), and Gr-1
 

 
 cells (mostly granulocytes). To detect trans-
ferred HBsAg-specific CD8
 

 
 CTL clones (6C2) in IHLs, cells
were stained with anti-CD8-FITC and H-2(L
 
d
 
)/HBs28–39 tet-
ramer-PE (provided by John D. Altman, Emory University
School of Medicine, Atlanta, GA). Samples were acquired on a
FACSCalibur™ flow cytometer, and the data was analyzed using
CELLQuest™ software (Becton Dickinson).
 
Quantitative Analyses of the Intrahepatic Content of the Transferred
CTLs.
 
Male CTLs were injected into female transgenic mice
and the animals were killed by 4 h after injection. Total liver
DNA was extracted as described previously. Primers specific for
the Sry gene contained in the Y chromosome (reference 25;
sense: 5
 

 
-GCAGTTGCCTCAACAAAACTGT-3
 

 
; antisense:
5
 

 
-AGGTGTGCAGCTCTACTCCAG-3
 

 
) and primers spe-
 
cific for GAPDH (sense: 5
 

 
-GGAAAGCTGTGGCGTGAT-3
 

 
;
antisense: 5
 

 
-CCAGTGAGCTTCCCGTTCAG-3
 

 
) were added
to 250 ng of total liver DNA and triplicate of each samples were
subjected to quantitative PCR in an iCycler apparatus (Bio-Rad
Laboratories) using SYBR Green as fluorescent dye (26).
 
Results
 
In Vitro Characteristics of HBsAg-specific CTLs.
 
An H-2
 
d
 
restricted, CD8
 

 
 CTL clone (designed 6C2) derived from
nontransgenic B10D2 mice (H-2
 
d
 
) that recognizes an
epitope (IPQSLDSWWTSL) located between residues 28–
39 of HBsAg was used in this study (9). As shown in Fig. 1,
clone 6C2 produced high levels of IFN-
 

 
 and TNF-
 
	
 
mRNAs after a 4-h stimulation in vitro with plate-bound
anti-CD3 mAbs. It is noteworthy that the in vitro and in
vivo (see below) characteristics of clone 6C2 are represen-
tative of various numbers of several independently derived
CD8
 

 
, H-2
 
d
 
-restricted, HBsAg-specific CTL clones, and
lines described previously (6, 9, 27, 28). Similar to other
independently derived CTL clones (data not shown), clone
6C2 did not express either (Crg2)IP-10 or Mig before or
after in vitro activation (Fig. 1). Clone 6C2 was found,
however, to express CXCR3, the common receptor for
(Crg2)IP-10 and Mig, although its expression was strongly
inhibited upon in vitro activation (Fig. 1). While it is for-
mally possible that this pattern of cytokine, chemokine, and
chemokine receptor expression may differ after CTL acti-
vation in the liver, these results indicate that these CTLs do
not express (Crg2)IP-10 nor Mig but they do express IFN-
 

 
,
TNF-
 
	
 
, and CXCR3.
 
 (Crg2)IP-10 and Mig Are Induced in the Liver of CTL-
injected HBV Transgenic Mice.
 
To relate the kinetics of liver
disease, antiviral effects, and cytokine expression with the
kinetics of chemokine and chemokine receptor induction
in the liver of CTL-injected HBV transgenic mice, eight
groups (three mice per group) of age-, sex-, and serum
Figure 1. In vitro characteristics
of HBsAg-specific CTLs. Total he-
patic RNA from clone 6C2 before
and after a 4-h stimulation in vitro
with plate-bound anti-CD3 mAbs
was analyzed by RNase protection
assay (RPA) for the expression of
various cytokines, (Crg2)IP-10, Mig,
and CXCR3 as indicated. The RNA
encoding the ribosomal protein L32
was used to normalize the amount of
RNA loaded in each lane.
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HBeAg-matched transgenic mice from lineage 1.3.32 were
injected intravenously with 10
 
7
 
 HBsAg-specific CTLs
(clone 6C2). Mice were bled and killed, and livers were
harvested at the indicated time points (Fig. 2). The results
were compared with those observed in livers from age-,
sex-, and serum HBeAg-matched transgenic littermates in-
jected with saline (NaCl) that were killed 2 d after NaCl
injection (Fig. 2).
After passive transfer of HBV-specific CTLs into HBV
transgenic mice, the transient liver disease (monitored bio-
chemically at multiple time points after injection as sALT
activity, a hepatocellular enzyme that is released into the
circulation by necrotic hepatocytes) reached maximum se-
verity at days 2–3 (Fig. 2) and completely disappeared
within 7 d (data not shown). Viral replication was inhibited
within 24 h (Fig. 2). Very low levels of IL-1
 
	
 
 and IL-1
 


 
(likely produced by Kupffer cells) were the only mRNA
species detected in the liver from NaCl-injected controls
(Fig. 1). Within 1 h after CTL injection, however, the
mRNA levels for these cytokines along with the mRNAs
for IFN-
 

 
 and TNF-
 
	
 
 (likely produced by the CTLs) in-
creased substantially, reaching their peak by 4 h (Fig. 2).
The induced transcripts remained elevated for at least 72 h
and they decreased toward baseline levels by day 5 (Fig. 2).
The kinetics and magnitude of the changes in IFN-
 

 
 and
TNF-
 
	
 
 gene expression reflect the kinetics of CTL entry
into the liver (maximal at 4–12 h; reference 5) and the rec-
 
ognition of antigen by these cells. It is also noteworthy that
the signal for the macrophage marker F480 increased by 1 h
and this was concomitant with the increase of proinflam-
matory cytokines such as IL-1
 
	
 
, IL-1
 


 
, IFN-
 

 
, and TNF-
 
	
 
.
This could be due to either the induction of F480 expres-
sion on activated resident macrophages (Kupffer cells) or
the rapid recruitment of circulating macrophages into the
liver.
The intensity of the signal for T cell (CD8, CD4, and
CD3) and macrophage (F4–80) markers was virtually max-
imal at 48–72 h (Fig. 2), indicating that host-derived in-
flammatory cells were recruited into the liver at these later
time points. Since the severity of liver disease was also
maximal at 48–72 h (Fig. 2), these results suggest that other
cells besides the transferred CTLs contribute to most of the
liver disease.
As shown in Fig. 2, the intrahepatic messages for
(Crg2)IP-10 and Mig were rapidly (within 4 h) and
strongly induced (
 

 
200- and 1,000-fold, respectively,
when compared by PhosphorImaging analysis with prein-
jected levels; note that the indicated bands for (Crg2)IP-10
and Mig correspond to an exposure time of the autorad of
16 and 2 h, respectively). Since neither (Crg2)IP-10 nor
Mig were produced by HBV-specific CTLs (Fig. 1), these
results indicate that other cells in the liver may represent
the source of these chemokines in our system. With similar
kinetics but lower levels of induction, we also detected sev-
Figure 2. Kinetics of HBV replication, disease, and
expression of cytokine, T cell and macrophage markers
and chemokines in the liver of CTL-injected HBV
transgenic mice. Age- and serum HBeAg–matched
male transgenic mice (three mice per group) from lin-
eage 1.3.32 were injected intravenously with 107 CTLs
(clone 6C2), killed at the indicated time points, and to-
tal hepatic DNA was analyzed for HBV replication by
Southern blot analyses. Bands corresponding to the in-
tegrated transgene, relaxed-circular (RC) and single-
stranded (SS) linear HBV DNA replicative forms are
indicated. The integrated transgene can be used to nor-
malize the amount of DNA bound to the membrane.
The mean sALT activity, measured at the time of au-
topsy, is indicated for each group and is expressed in U/l.
Total hepatic RNA from the same mice was also ana-
lyzed by RPA for the expression of T cell (CD3, CD4,
and CD8) and macrophage (F480) markers, various cy-
tokines, chemokines, and CXCR3 as indicated. The
RNA encoding the ribosomal protein L32 was used to
normalize the amount of RNA loaded in each lane.
Results were compared with those observed in livers
pooled from 10 age-, sex-, and serum HBeAg–matched
transgenic littermates injected with saline (NaCl).
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eral C-C chemokines, including macrophage inflammatory
protein (MIP)-1	, MIP-1
, and MIP-2 (chemoattractants
for lymphocytes and macrophages), monocyte chemotactic
protein (MCP)-1 and MCP-3 (chemoattractants for mono-
cytes/macrophages) and lymphotactin (chemoattractant for
lymphocytes and NK cells; Fig. 2).
The C-C chemokines C10 and regulated on activation,
normal T cell expressed and secreted (RANTES; chemoat-
tractants for monocytes/macrophages) showed a more de-
layed peak of induction that was maximal by days 2–5 (Fig.
2), indicating that other factors beside the activation of the
transferred CTLs contributed to their induction.
To determine which cells produce (Crg2)IP-10 and
Mig, the hepatic content of both chemokine mRNAs was
analyzed by in situ hybridization analysis of livers derived
from HBV transgenic animals killed at various time points
after CTL injection. Interestingly, as shown in Fig. 3 for
two representative livers harvested 4 h after CTL injection,
(Crg2)IP-10 (Fig. 3 D) and Mig (Fig. 3 B) mRNAs were
detected not only in nonparenchymal cells (Kupffer cells
and infiltrating inflammatory cells, arrowheads) but, even
more abundantly, in parenchymal cells (hepatocytes) of the
liver. In keeping with the fact that the intrahepatic levels of
Mig mRNA were five times more abundant than those for
(Crg2)IP-10 (Fig. 2), it is not surprising that a higher per-
centage of liver cells were positive for the former chemo-
kine (Fig. 3 B). It is also noteworthy that (Crg2)IP-10
mRNA was more abundant in liver cells (particularly
Figure 3. Intrahepatic distri-
bution of (Crg2)IP-10 and Mig
mRNA in NaCl- and CTL-
injected livers. Livers from HBV
transgenic mice (lineage 1.3.32)
that were injected 4 h earlier ei-
ther with saline (NaCl) or HBV-
specific CTLs were analyzed for
the expression of Mig (A and B)
or (Crg2)IP-10 (C and D)
mRNA by in situ hybridization
using specific 33[P]-labeled ribo-
probes. Note that most Mig- or
(Crg2)IP-10 RNA is contained
in the hepatocytes of CTL-
injected livers (B and D). Mig-
or (Crg2)IP-10–positive non-
parenchymal cells (arrowheads,
B and D) and Mig- or (Crg2)IP-
10–negative apoptotic hepato-
cytes (asterisks, B and D) and in-
flammatory cells (arrows, A) are
also indicated (H&E; original
magnification: 400).
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hepatocytes) surrounding small inflammatory foci (Fig. 3
D), while Mig mRNA was more homogeneously distrib-
uted throughout the organ (which was more easily ob-
served at shorter exposures, not shown). No signal for
(Crg2)IP-10 mRNA was detected in the liver of NaCl-
injected control mice that were killed by 4 h after injection
(Fig. 3 C). Very low levels of Mig mRNA were observed
in similar control animals which were almost exclusively
detected within hepatocytes (Fig. 3 A) that surrounded
rare, small foci of Mig-mRNA negative inflammatory cells
(Fig. 3 A, arrows). No expression of either chemokine was
detected in apoptotic hepatocytes (asterisks, Fig. 3 B and
D). Finally, a similar induction of (Crg2)IP-10 and Mig
was observed at the 24 and 48 h time points (data not
shown). All together, these results indicate that the hepato-
cytes represent a major source of (Crg2)IP-10 and Mig
mRNAs in the CTL-injected livers.
The Intrahepatic Induction of (Crg2)IP-10 and Mig Is Medi-
ated by IFN- Produced by the Transferred CTLs. Previous
studies have shown that IFN- is a powerful inducer of
both (Crg2)IP-10 and Mig (11). To determine whether
the induction of (Crg2)IP-10 and Mig was mediated by
IFN- in our system as well, we monitored the ability of
hamster mAbs specific for IFN- to modulate the intrahe-
patic expression of these two chemokines after CTL injec-
tion. Two groups (three mice per group) of age-, sex-,
and serum HBeAg–matched transgenic mice (lineage
1.3.32) were injected with either IFN- mAb or irrele-
vant hamster IgG prior transfer of 107 HBsAg-specific
CTLs (clone 6C2) and the mice were killed 24 h after
CTL administration. As shown in Fig. 4 (note that the in-
dicated bands for (Crg2)IP-10 and Mig correspond to an
exposure time of the autorad of 16 and 2 h, respectively),
the induction of (Crg2)IP-10 and Mig was almost com-
pletely blocked in two representative mice that received
Abs to IFN-. The levels of (Crg2)IP-10 were induced
120-fold (when compared by phosphor imaging analysis
with NaCl-injected control mice) and treatment with
IFN- mAb reduced this increase by 24-fold. These re-
sults indicate that the induction of these chemokines de-
pends on IFN-.
To determine the relative contribution of the trans-
ferred CTLs versus host-derived inflammatory cells in the
IFN-–dependent induction of (Crg2)IP-10 and Mig, we
examined the expression levels of these chemokines in
CTL-injected livers from HBV transgenic mice that were
crossed with mice genetically deficient for IFN-. Two
groups (three mice per group) of age- (8–10 wk), sex-
(male), and serum HBeAg–matched animals that were ei-
ther heterozygous (/) or homozygous (/) for the
IFN- null mutation were injected with 107 IFN-–pro-
ducing HBsAg-specific CTLs (clone 6C2) and killed 24 h
later. As shown in Fig. 4 for two representative mice per
group, the intrahepatic levels of (Crg2)IP-10 and Mig
mRNAs were comparable in both groups of mice, indicat-
ing that the amount of IFN- produced by passively trans-
ferred CTLs mediates the induction of these two chemo-
kines.
 (Crg2)IP-10 and Mig only Partially Mediate the Recruitment
of HBV-specific CTLs. To define the role of (Crg2)IP-10
and Mig in the recruitment of transferred HBV-specific
CTLs into the liver, we monitored the ability of anti–
(Crg2)IP-10 and anti-Mig neutralizing Abs to modulate
this process. The recruitment of the passively transferred
clone 6C2 (originally produced in male mice; reference 9)
was measured by quantifying the amount of Sry-specific se-
quences (Sry is a gene contained in the Y chromosome
(25)) in the liver of HBV transgenic female mice (lineage
1.3.32) using real time PCR. The recruitment of the trans-
ferred CTLs was also measured by isolating IHLs and quan-
tifying the number of tetramer-specific CTLs using FACS®
analysis. 1 ml of either a cocktail of anti–(Crg2)IP-10 and
anti-Mig neutralizing rabbit Ig or NRS was administered
intraperitoneally into two groups (three mice per group) of
age- (8–10 wk) and serum HBeAg–matched female trans-
genic mice (lineage 1.3.32) twice, first 16 h before and then
simultaneously with the transfer of 5  106 HBsAg-specific
CTLs (clone 6C2). Mice were killed 4 h after CTL transfer
and total liver DNA was extracted.
250 ng of total liver DNA derived from each mouse
were subjected to quantitative real time PCR using Sry-
specific primers. GAPDH-specific primers were used to
normalize the amount of input DNA. Sry-specific ampli-
cons were detected at similar threshold cycles (1 cycle
difference) in mice that received either control or anti-
chemokine Abs (data not shown). Since this assay discrim-
inates differences of twofold or more, these results indicate
that the number of CTLs that reached the liver at 4 h after
injection was within a twofold difference between the two
groups of mice. Similar results were obtained when the
Figure 4. The intrahepatic induction of (Crg2)IP-10 and Mig is medi-
ated by IFN- produced by the transferred CTLs. (Left panel) Age- and
serum HBeAg–matched male transgenic mice (lineage 1.3.32) were intra-
peritoneally injected with 250 g of hamster mAbs to IFN- and killed
24 h after CTL administration. Control mice (Irr Ab) were simultaneously
injected with 250 g of irrelevant hamster IgG before CTL transfer and
killed at the same time after CTL administration. (right panel). Age- and
serum HBeAg–matched male transgenic mice (lineage 1.3.46) that were
either heterozygous (/) or homozygous (/) for the IFN- null
mutation were injected with 107 CTLs (clone 6C2) and killed 24 h later.
Total hepatic RNA was analyzed for (Crg2)IP-10, Mig, and CXCR3 as
indicated. The RNA encoding the ribosomal protein L32 was used to
normalize the amount of RNA loaded in each lane. Results were com-
pared with those observed in livers pooled from 10 age-, sex-, and serum
HBeAg–matched transgenic littermates injected with saline (NaCl).
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number of tetramer-positive CTLs was quantitated in
these same livers. Tetramer-positive CTLs accounted for
0.97 and 1.3% of the total IHL recovered from the liver of
mice that received either control or antichemokine Abs,
respectively. These conclusions are also supported by the
finding that the levels of IFN- mRNA (a marker of anti-
gen recognition by CTLs) in control mice were induced
only about twofold more than those observed in the liver
of the mice treated with antichemokine Abs. (Fig. 5).
This reiterates the fact that the recruitment of the pas-
sively transferred CTLs was only partially dependent on
(Crg2)IP-10 and Mig.
(Crg2)IP-10 and Mig Do Not Mediate the Antiviral Potential
of HBV-specific CTLs. To define the role of (Crg2)IP-10
and Mig in the antiviral potential of HBV-specific CTLs
into the liver, we monitored the ability of anti–(Crg2)IP-
10 and anti-Mig neutralizing Abs to modulate the CTL-
dependent antiviral effect.
As before, 1 ml of either a cocktail of anti–(Crg2)IP-10
and anti-Mig neutralizing rabbit Ig or NRS was adminis-
tered intraperitoneally into four groups (three mice per
group) of age- (8–10 wk), sex-, and serum HBeAg-
matched transgenic mice (lineage 1.3.32) twice, first 16 h
before and then simultaneously with the transfer of 2.5 
106 HBsAg-specific CTLs (clone 6C2). Mice were bled
and killed, and livers were harvested 24 and 48 h later and
results were compared with those observed in livers pooled
from 10 age-, sex-, and serum HBeAg–matched transgenic
littermates injected with saline (NaCl).
As shown in Fig. 5, simultaneous administration of
(Crg2)IP-10 and Mig Abs did not block the CTL-induced
inhibition of hepatic HBV replication observed at 24 and
48 h that was also detected in control mice that received
NRS. These results indicate that (Crg2)IP-10 and Mig do
not directly inhibit HBV replication themselves nor do they
regulate the antiviral potential of HBV-specific CTLs in
our system. The fact that HBV replication was inhibited in
this experiment in association with very modest elevations
of sALT reiterate the fact that the CTL-dependent antiviral
effect is not due to the destruction of hepatocytes (6, 7).
(Crg2)IP-10 and Mig Mediate the Recruitment of Antigen-
nonspecific Host-derived Inflammatory Cells that Are Responsible
for Most of the Liver Disease. Importantly, treatment with
antichemokine Abs diminished the severity of the liver dis-
ease, as measured biochemically or histologically, thus indi-
cating the neutralization ability of these antibodies in our in
vivo system. At the time of autopsy, the sALT activity of
mice that received antichemokine Abs was reduced two-
to threefold when compared with control animals at differ-
ent time points (Fig. 5). Since in this experiment HBV
transgenic mice (those killed at 24 and 48 h) received a
lower number of CTLs (2.5  106) than the mice shown in
Fig. 2 (107), it is not surprising that sALT levels (in control
animals) were also lower: mean  479  91 (Fig. 5) versus
mean  940  146 (Fig. 2) at 24 h and mean  374  83
(Fig. 5) versus mean  2686  339 (Fig. 2) at 48 h. This is
consistent with previous reports showing that in this system
sALT elevation is CTL dose dependent (6, 9).
As shown in Fig. 6 (top), histological analysis of the liv-
ers from animals treated with control Abs demonstrated
necroinflammatory foci scattered throughout the liver pa-
renchyma, containing apoptotic hepatocytes (asterisks),
lymphomononuclear (arrows and arrowheads), and poly-
morphonuclear cells. Antichemokine treatment did not
significantly reduce the number of necroinflammatory foci
(scored as apoptotic hepatocytes and inflammatory cells) by
Figure 5. (Crg2)IP-10 and Mig activity do not mediate
the antiviral potential of HBV-specific CTLs but mediate
part of the accompanying liver disease. 1 ml of either a
cocktail of anti–(Crg2)IP-10 and anti-Mig neutralizing
rabbit Ig or NRS was administered intraperitoneally into
six groups (three mice per group) of age- (8–10 wk), sex-,
and serum HBeAg–matched transgenic mice (lineage
1.3.32) twice, first 16 h before and then simultaneously
with the transfer of HBsAg-specific CTLs (clone 6C2).
Mice were bled and killed, and livers were harvested 4, 24,
or 48 h later. Total hepatic DNA was analyzed for HBV
replication by Southern blot analyses. Bands corresponding
to the integrated transgene, relaxed-circular (RC) and sin-
gle-stranded (SS) linear HBV DNA replicative forms are
indicated. The integrated transgene can be used to normal-
ize the amount of DNA bound to the membrane. The
mean sALT activity, measured at the time of autopsy, is in-
dicated for each group and is expressed in U/l. Total he-
patic RNA from the same mice was also analyzed by RPA
for the expression of various cytokines as indicated. The
RNA encoding the ribosomal protein L32 was used to
normalize the amount of RNA loaded in each lane. Re-
sults were compared with those observed in livers pooled
from 10 age-, sex-, and serum HBeAg–matched transgenic
littermates injected with saline (NaCl).
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24 and 48 h after CTL injection, as measured by quantita-
tive morphometric analysis (79 7.6 [24 h] and 92  12.6
[48 h] in Ab-treated mice versus 91 11.2 [24 h] and
109  13.2 [48 h] in control animals: these numbers rep-
resent the mean  SEM per 100 high power fields, corre-
sponding to 4 mm2 of liver tissue). This again indicates
that similar numbers of CTLs reached the liver in both
groups of animals. Importantly, however, antichemokine
treatment reduced the size of necroinflammatory foci,
both by 24 (data not shown) and 48 h (Fig. 6, right panels)
after CTL injection. The average area of these foci (2.2 
1.3  103 mm2) was about twofold smaller than that ob-
served in control mice (4.0  2.2  103 mm2) as mea-
sured by morphometric analysis. Many fewer lympho-
mononuclear cells (Fig. 6, top right panel, arrows and
arrowheads) were detectable in the foci, while the number
of polymorphonuclear cells was little or not reduced (Fig.
6, top right panel).
To determine the characteristics of the intrahepatic in-
flammatory infiltrate in the same livers, the absolute num-
ber of IHLs recovered was quantitated, and the phenotype
of the recruited inflammatory cell subsets was determined
by FACS® analysis. Two additional groups of transgenic
control mice (three mice per group) were injected with
NaCl alone to produce a baseline for the analysis of the in-
trahepatic infiltrate by flow cytometry.
When compared with NaCl-injected controls (Fig. 7,
gray bars), the total number of IHLs as well as most cell
subsets significantly increased in the liver of CTL-treated
mice that received control Abs (Fig. 7, white bars). The to-
tal number of IHLs increased over fivefold at 24 and 48 h
after CTL injection, corresponding with a commensurate
increase in: (i) NK1.1/CD3 and DX5 cells (NK cells)
(seven- to eightfold and 10–12-fold at 24 and 48 h, respec-
tively); (ii) CD3/NK1.1 cells (T cells) (about eightfold at
both time points); (iii) CD8 cells (mostly CTLs) (about
five- and eightfold at 24 and 48 h, respectively); (iv) CD4
(mostly Th cells) (5 and 3.5-fold at 24 and 48 h, respec-
tively); (v) CD11b/CD11c (mostly lymphoid dendritic
cells) (about threefold at both time points); (vi) CD11b/
CD11c cells (mostly myeloid dendritic cells) (10- and
16-fold at 24 and 48 h, respectively); (vii) CD11b/
CD11c (mostly macrophages) (about eight at both time
points); (viii) CD19 (B cells) (almost twofold at both time
points) and (ix) Gr-1 cells (mostly granulocytes) (10-
fold at both time points). It is also noteworthy that the
number of NKT cells was reduced two- to threefold in
CTL-injected livers (with and without antichemokine
Figure 6. Passive neutralization of (Crg2)IP-10 and Mig reduced the recruitment of lymphomononuclear cells and the size of the intrahepatic inflam-
matory foci. (Top) Histological analysis of the necroinflammatory foci detected in the livers from animals treated either with control Abs (NRS, left) or
antichemokine Abs (	Mig  	IP-10, right) that were killed 48 h after CTL transfer. Cells displaying the histological features of apoptotic hepatocytes
(asterisks), lymphocytes (arrows), and macrophages (arrowheads) are indicated. Cells displaying the histological features of polymorphonuclear cells are
not indicated. Note that fewer apoptotic hepatocytes and lymphomononuclear cells were detectable in the foci of mice treated with antichemokine Abs
(right). (Bottom) Histological analysis of the same livers at lower magnification displaying several necroinflammatory foci (arrowheads). Original magnifi-
cations: 1,000 (top) and 100 (bottom).
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treatment) when compared with the number of NKT cells
isolated from NaCl-injected control animals (data not
shown). This presumably reflects activation induced cell
death of NKT cells, as previously shown in other systems
(29, 30). As also shown in Fig. 7, antichemokine treatment
reduced the number of total IHLs recruited (black bars) by
2.5 and 1.7 fold at 24 and 48 h, respectively. Along with
this, the number of all cell subsets recruited was lower in
mice that were killed at 24 h and received antichemokine
Abs (Fig. 7, black bars). The most pronounced decreases
were observed for NK cells, myeloid dendritic cells, and
CTLs (all of which are known to express CXCR3; refer-
ences 31–33). The number of Th cells, macrophages, lym-
phoid dendritic cells, B cells, and granulocytes also de-
creased, but to a lesser extent (Fig. 7). By 48 h, very little
difference in the number of Th cells and granulocytes was
observed between the two groups, while a substantial dif-
ference remained for all other subsets (Fig. 7). All together,
these results indicate that in association with the reduction
of sALT elevation (Fig. 5) and the size of the inflammatory
foci (Fig. 6), passive neutralization of (Crg2)IP-10 and Mig
reduced the recruitment of most cell subsets and particu-
larly those (NK cells, myeloid dendritic cells, and CTLs)
known to express CXCR3.
Discussion
In this study we showed that after the passive transfer of
HBV-specific CTLs into transgenic mice that replicate
HBV at high levels in their hepatocytes, chemokines such
as (Crg2)IP-10 and Mig were rapidly and strongly induced
in the liver. Interestingly, the transferred CTLs did not
produce either chemokine. Rather, upon antigen recogni-
tion, they secreted IFN-, which in turn activated both
nonparenchymal and, especially, parenchymal cells of the
liver to express high levels of (Crg2)IP-10 and Mig.
The notion that hepatocytes represent a major source of
these chemokines in the inflamed liver is supported by a re-
cent study that showed IFN-–dependent expression of
(Crg2)IP-10 and Mig in primary hepatocytes derived from
IL-2/IL-12 treated mice (13). These observations may also
shed some light into the pathogenesis of other liver condi-
tions (i.e., ischemia/reperfusion, biliary atresia, liver cancer,
protozoan infections) where the hepatic expression of IP-
10 and Mig has been detected (14, 34–37). All together,
these results suggest that the hepatocyte (the cell type that
sustains viral replication during natural infection; reference
38) may play an important role in the recruitment of in-
flammatory cells into the liver and, perhaps, in its own an-
tiviral defense. Given that during natural infection the peak
influx of T cells into the organ is delayed by several weeks
after the peak of HBV replication (39), it is also tempting
to speculate that the virus may interfere with the produc-
tion of these chemokines in order to counteract the antivi-
ral effector functions of immune cells. Future studies aimed
at monitoring the intrahepatic profiles of chemokine ex-
pression in infected human or chimp livers will address this
interesting hypothesis.
Passive neutralization of (Crg2)IP-10 and Mig in vivo
did not significantly reduce the recruitment of the trans-
ferred CTLs and the intrahepatic induction of IFN- was
reduced by about twofold at the 4-h time point. The no-
tion that the early recruitment of the transferred CTLs was
not particularly affected by neutralization of (Crg2)IP-10
and Mig may be due to the fact that other chemokine–
chemokine receptor interactions were still operative in our
system. In support of this, we found that in addition to
CXCR3 (the receptor specific for (Crg2)IP-10 and Mig,
Fig. 1) the transferred CTLs expressed CCR1, CCR2,
CCR4, CCR5, and CCR7 (data not shown) and ligands
Figure 7. Passive neutralization of (Crg2)IP-10 and Mig reduced the
recruitment of most cell subsets and particularly lymphomononuclear cells
such as NK cells, myeloid dendritic cells, and CTLs. IHLs analysis in the
same animals described in the legend to Fig. 5. Livers were weighed at the
time of autopsy. IHLs were isolated from two liver lobes of a known
weight and analyzed by flow cytometry. The indicated numbers of total
IHLs and different cell subsets represent the numbers detected in the
whole liver.
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specific for these receptors (MIP-1	, MIP-1
, RANTES,
MCP-1, and MCP3) were induced in the CTL-injected
livers (Fig. 2). It is also noteworthy that the expression of
CXCR3 by the HBV-specific CTLs was strongly inhibited
upon in vitro activation of (Fig. 1). This effect may explain
the lack of intrahepatic detection of CXCR3 mRNA into
the liver at the early time points (4–12 h) after CTL transfer
(Fig. 2), when CTL entry into the liver and the recognition
of antigen by these cell is maximal. Inhibition of chemo-
kine receptor mRNA expression after in vitro activation
has also been reported for influenza-virus specific CTLs
(40) and it is thought to play an important role in the regu-
lation of the chemokine system (41). Lack of detection of
intrahepatic CXCR3 mRNA at the early time points could
also be due to the relative lower abundance of this message
in the total hepatic RNA population as compared with its
higher abundance in the CTL-derived RNA population
described in Fig. 1. At any rate, it is worth mentioning that
the message for CXCR3 increased at later time points (24–
72 h), probably reflecting the recruitment of host-derived,
antigen-nonspecific CXCR3-inflammatory cells.
The extent to which the recruitment of the transferred
CTLs was affected by the passive neutralization of
(Crg2)IP-10 and Mig at later time points (24 and 48 h) was
not directly measured. However, no difference in the intra-
hepatic levels of IFN- and TNF-	 mRNAs was observed
between antichemokine Ab- and NaCl-treated mice (Fig.
5). Again, since the intrahepatic expression of these cyto-
kines likely reflect the entry of the IFN-- and TNF-	–
expressing transferred CTLs into liver and the recognition
of antigen by these cells, these results suggest that (Crg2)IP-
10 and Mig did not mediate the recruitment of the trans-
ferred CTLs at these time points. In keeping with this, the
number of hepatic inflammatory foci was not significantly
reduced and HBV replication was still strongly inhibited in
the animals that received antichemokine Abs (Fig. 5).
These results also indicate that (Crg2)IP-10 and Mig do not
have a direct antiviral activity against HBV and they do not
mediate the antiviral potential of HBV-specific CTLs in
our system. Pertinent to this, it is worth mentioning that
while recent studies in vivo have demonstrated a role for
(Crg2)IP-10 and Mig in controlling the replication of vi-
ruses such as vaccinia virus (15) mouse hepatitis virus (16,
17) and MCMV (18), they didn’t demonstrate that those
chemokines directly inhibited viral replication, since these
viruses can reinfect potentially cured cells and obscure the
observations. In our studies, however, the lack of a direct
antiviral potential of (Crg2)IP-10 and Mig against HBV
could be demonstrated because HBV is not infectious for
mice and it is produced by each hepatocyte without
spreading from cell to cell (3).
Importantly, passive neutralization of (Crg2)IP-10 and
Mig significantly reduced the recruitment of lympho-
mononuclear cells and the size of the intrahepatic inflam-
matory foci (Fig. 6) as well as the severity of the CTL-
dependent liver disease (Fig. 5). The notion that viral
replication was strongly inhibited in antichemokine Ab-
treated animals in which very little liver disease was ob-
served (Fig. 5) reiterates the fact that the antiviral potential
of the CTLs is mainly mediated by cytokine-dependent,
noncytolytic mechanisms, as demonstrated previously
(6–8, 42).
The recruitment of most cell subsets and particularly
those (NK cells, myeloid dendritic cells, and CTLs)
known to express CXCR3 (31–33) was inhibited in anti-
chemokine Ab-treated animals by 5–10-fold at the 24 and
48 h time points (Fig. 7). The recruitment of Th cells was
also reduced, albeit to a lesser extent (less than twofold by
24 h and virtually no reduction by 48 h, Fig. 7). Since Th
cells are known to express CXCR3 (43, 44), these results
may suggest that other chemoattractant factors play a more
important role in the recruitment of these cells into the
liver. Similar reasons may explain the partially reduced re-
cruitment of cells not known to express CXCR3 (macro-
phages and granulocytes) which was mostly observed by
24 h (Fig. 7).
The association of reduced liver disease with reduced re-
cruitment of host-derived, antigen-nonspecific inflamma-
tory cells into the liver implies that these cells can amplify
the liver damage initiated by the antigen-specific CTLs.
This conclusion is also supported by the fact that the kinet-
ics and magnitude of liver disease (maximal at 48 h, Fig. 2)
were delayed compared with the peak of intrahepatic ex-
pression of IFN- and TNF-	 (maximal at 4 h, Fig. 2),
which, as suggested before, are likely to mirror the entry
into the liver of antigen-specific CTLs and the recognition
of antigen by these cells. The pathogenetic mechanisms
whereby antigen-nonspecific inflammatory cells may in-
duce liver damage are not understood. Future studies will
attempt to address this important issue. It is also notewor-
thy that the HBV transgenic mice used in this study are
profoundly immunologically tolerant to the virus, particu-
larly at the T cell level (4). This notion coupled with the
short term nature of the experiments herein described
makes extremely unlikely that host-derived antigen-spe-
cific T cells contributed to the pathogenesis of liver disease
in our system.
In conclusion, we found that blocking (Crg2)IP-10 and
Mig in vivo reduces the recruitment of host-derived in-
flammatory cells (particularly lymphomononuclear cells)
into the liver and the severity of the liver disease without
affecting the IFN-–dependent antiviral potential of anti-
gen-specific CTLs. We conclude that target organ produc-
tion of (Crg2)IP-10 and Mig leads to an exaggerated re-
cruitment of host-derived inflammatory cells to the liver
which play an important role in the pathogenesis of liver
disease in our system. Similar mechanisms may contribute
to the pathogenesis of viral hepatitis in man, where, like in
our system, the number of HBV-specific T cells detected
in the liver is outnumbered by recruited nonvirus-specific
T cells (2, 45) and other inflammatory cells (46). Since the
transgenic mice used in this study are not infected by
HBV, it is possible that during natural infection CTL-inde-
pendent mechanisms (i.e., intrahepatic activation of NK
and/or NK T cells) could induce IFN- and initiate the
cascade of pathogenetic events that results in the recruit-
1765 Kakimi et al.
ment of antigen nonspecific inflammatory cells to the liver.
However, it must be noted that the IFN-–dependent sec-
ondary processes that lead to the intrahepatic recruitment
of inflammatory cells during natural infection are likely to
be quite similar to those described in this study, irrespec-
tive of the nature of the cell type that originally produces
this cytokine. In keeping with this, it is worth mentioning
that the intrahepatic expression of IP-10 and Mig is in-
duced during chronic HCV infection along with an in-
creased number of liver infiltrating CXCR3-expressing T
cells (20). Detection of HCV-specific CXCR3 CTLs has
been associated with phases of enhanced liver disease in
HCV-infected patients (47). Based on the studies herein
described, the notion that neutralization of IP-10 and Mig
is associated with maintenance of antiviral effects but di-
minished tissue damage may help the design of potential
immunotherapeutic approaches for the treatment of HBV
infection in chronically infected patients.
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